Atlas Trials

Australasian Gastro-Intestinal Trials Group

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Australasian Gastro-Intestinal Trials Group

RecordFirmDate
Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer (NCT06604533)Australasian Gastro-Intestinal Trials Group2025-07-07
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (NCT06345079)Australasian Gastro-Intestinal Trials Group2024-10-14
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) (NCT06441747)Australasian Gastro-Intestinal Trials Group2024-09-23
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer (NCT05694936)Australasian Gastro-Intestinal Trials Group2023-01-23
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer (NCT06094140)Australasian Gastro-Intestinal Trials Group2022-05-20
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NCT05042128)Australasian Gastro-Intestinal Trials Group2022-04-13
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (NCT05862051)Australasian Gastro-Intestinal Trials Group2021-12-14
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study (NCT06290505)Australasian Gastro-Intestinal Trials Group2021-12-08
RegoNivo vs Standard of Care Chemotherapy in AGOC (NCT04879368)Australasian Gastro-Intestinal Trials Group2021-05-05
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (NCT04089150)Australasian Gastro-Intestinal Trials Group2019-10-01
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (NCT03647839)Australasian Gastro-Intestinal Trials Group2018-09-06

Track Australasian Gastro-Intestinal Trials Group automatically

Every clearance here is in the API, with alerts when new ones post.